ARTICLE | Clinical News

Catalyst Pharma preclinical data

November 15, 2010 8:00 AM UTC

In rat and mice models of epilepsy, CPP-115 displayed similar anticonvulsant efficacy to that of vigabatrin, but with lower doses. Separately, CPP-115 eliminated cocaine-related conditioned place preference and significantly reduced cocaine-induced dopamine surge at doses more than 100 times lower than that needed by vigabatrin to achieve the same effect. Additionally, exposure to CPP-115 for 90 days led to significantly less retinal damage compared to vigabatrin (p<0.05). ...